Biocortex

BioCorteX (BIOCORTEX LTD) is a London-based techbio company working at the intersection of computational simulation and microbiome biology. Its stated premise is that every pharmaceutical interacts with the bacteria living in and on the human body, and that these bacterial populations differ between geographies and populations — a difference the company positions as a reason an asset can succeed in one region and fail in another. On that basis BioCorteX offers what it calls in-silico bridge trials, which map drug-microbiome interaction before clinical study so that scientific, regulatory and commercial teams can move an asset from one population to another. The company describes its approach as mechanism-first, transparent and auditable, and contrasts it with AI methods that predict whether an asset works rather than for whom and why.

The company's flagship product at the time of its seed round was Carbon Mirror, described as a first-principles computer simulation combining physics, chemistry and computational techniques to model interactions between the microbiome, host and treatment, and to assess or predict an individual's response to treatment from their microbiome profile. Company materials liken the simulation approach to methods used in designing nuclear reactors and jet engines. More recently the company's site describes NeoCorteX as the platform behind every bridge trial. BioCorteX has also been characterised as building a clinically validated AI-driven human-microbiome platform, and its registered nature of business under UK filings is research and experimental development on biotechnology (SIC 72110).

Founding story

The company was founded in response to what its founders characterised as the failure of prevailing drug development methods to account for drug-microbiome interactions in individual health outcomes. It was co-founded by Dr Nik (Nikhil) Sharma, a clinician who serves as Chief Executive Officer, and Dr Mo (Muhannad) Alomari, Chief Technology Officer.

Business model

BioCorteX operates as a technology and services provider to drug developers rather than as a therapeutics developer, inviting prospective clients to "bring us your asset" for in-silico bridge trials run on its platform. Earlier positioning framed the value chain as benefiting pharmaceutical companies in clinical trial design, clinicians and patients in treatment decisions, and payers through better therapy selection.

Traction

Disclosed traction is limited to the completed $5 million seed financing from specialist life-science and technology investors, the addition of two investor partners to the board, and unnamed partnerships referenced on the company website. UK filings show accounts made up to 31 March 2025.

Latest developments

The company's website now frames its offering as in-silico bridge trials underpinned by the NeoCorteX toolkit, positioned against AI prediction tools, and operates under both biocortex.co.uk and biocortex.com. Companies House records the company as active with accounts last made up to 31 March 2025.